Parexel, a prominent global clinical research organization (CRO), has named Jim Anthony as the chief commercial officer (CCO) and president of Parexel Biotech. This appointment aims to enhance the company’s customer-centric approach and its capability to foster growth and bring value. Anthony previously led Parexel Biotech since its establishment in 2019 and most recently held the position of president and global head of Parexel Biotech. As part of the organization’s long-term succession planning, Conal Burgess, the current president and global head of Enterprise Partnerships, will be stepping down from his role at Parexel by December 31, 2025.
Peyton Howell, CEO of Parexel, emphasized the importance of adaptation and innovation in the evolving landscape of the industry and clinical development. The addition of a chief commercial officer aligns with Parexel’s strategic focus on meeting customer requirements and driving growth initiatives. Anthony’s proven leadership in developing Parexel Biotech from its inception to a significant contributor, generating approximately half of Parexel’s global revenue, makes him well-suited for this expanded role. The company looks forward to leveraging Anthony’s expertise to further enhance the commercial organization, while expressing gratitude for Conal Burgess’s contributions to Parexel’s achievements.
With over 25 years of experience in pharmaceutical development and CRO operations, Anthony’s background positions him well for his new responsibilities. Having joined Parexel in 2010 as the vice president of North America Business Development, he has progressed through various leadership roles such as corporate vice president, Enterprise Account Leader, and executive vice president and global head of Parexel Biotech before assuming his current position in 2023. In his new capacity, Anthony will be responsible for overseeing the strategic relationships with both biotech and pharmaceutical clients globally, utilizing Parexel’s extensive range of solutions and industry-leading expertise in phase I-IV clinical development to expedite the delivery of transformative therapies to the market.
Anthony’s vision includes a holistic approach towards all customer segments, from large pharmaceutical companies to emerging biotechs, enabling Parexel to capitalize on its strengths, navigate market challenges swiftly, and fortify its strategies to bolster growth. His leadership will play a pivotal role in advancing the company’s mission to accelerate the development and market entry of life-changing therapies. Parexel anticipates that Anthony’s guidance will further solidify its position in the industry and expand its footprint across diverse customer categories.
- Jim Anthony appointed as Parexel’s CCO and President of Biotech Operations
- Conal Burgess to transition from his role as part of long-term succession planning
- Anthony’s extensive experience in pharmaceutical development and CRO operations
- Strategic focus on enhancing customer relationships and driving growth initiatives through Anthony’s leadership
Tags: biotech
Read more on pharmabiz.com